- Home
- NODK vs ZNTL Comparison
NODK vs ZNTL Comparison
Compare NODK & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- ZNTL
- Stock Information
- Founded
- NODK 1946
- ZNTL 2014
- Country
- NODK United States
- ZNTL United States
- Employees
- NODK N/A
- ZNTL N/A
- Industry
- NODK Property-Casualty Insurers
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- ZNTL Health Care
- Exchange
- NODK Nasdaq
- ZNTL Nasdaq
- Market Cap
- NODK 289.0M
- ZNTL 118.3M
- IPO Year
- NODK 2017
- ZNTL 2020
- Fundamental
- Price
- NODK $13.20
- ZNTL $1.50
- Analyst Decision
- NODK
- ZNTL Buy
- Analyst Count
- NODK 0
- ZNTL 6
- Target Price
- NODK N/A
- ZNTL $6.53
- AVG Volume (30 Days)
- NODK 10.0K
- ZNTL 757.8K
- Earning Date
- NODK 11-05-2025
- ZNTL 11-06-2025
- Dividend Yield
- NODK N/A
- ZNTL N/A
- EPS Growth
- NODK N/A
- ZNTL N/A
- EPS
- NODK 0.07
- ZNTL N/A
- Revenue
- NODK $310,389,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- NODK N/A
- ZNTL N/A
- Revenue Next Year
- NODK N/A
- ZNTL N/A
- P/E Ratio
- NODK $187.31
- ZNTL N/A
- Revenue Growth
- NODK N/A
- ZNTL N/A
- 52 Week Low
- NODK $12.01
- ZNTL $1.01
- 52 Week High
- NODK $17.24
- ZNTL $4.44
- Technical
- Relative Strength Index (RSI)
- NODK 45.04
- ZNTL 43.40
- Support Level
- NODK $13.16
- ZNTL $1.49
- Resistance Level
- NODK $13.41
- ZNTL $1.82
- Average True Range (ATR)
- NODK 0.22
- ZNTL 0.10
- MACD
- NODK -0.04
- ZNTL -0.01
- Stochastic Oscillator
- NODK 23.12
- ZNTL 13.70
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.